Adrenergic modifiers - Biotech, Pharma and Life Science Channel

14:22 EDT 29th August 2014 | BioPortfolio

PubMed Articles [376 Associated PubMed Articles listed on BioPortfolio]

Synthesis of a New Cyclosporine-based Stationary Phase and Separation Behaviors toward Aromatic Positional Isomers by High-Performance Liquid Chromatography.

A new cyclosporine-bonded stationary phase has been synthesized through the Staudinger reaction between azido cyclosporine A (CsA) and aminopropyl silica gel and applied in separations of six disubsti...

The "Bear" Essentials: Actualistic Research on Ursus arctos arctos in the Spanish Pyrenees and Its Implications for Paleontology and Archaeology.

Neotaphonomic studies of large carnivores are used to create models in order to explain the formation of terrestrial vertebrate fossil faunas. The research reported here adds to the growing body of kn...

Melanocyte biology and function with reference to oral melanin hyperpigmentation in HIV-seropositive subjects.

The colour of normal skin and of oral mucosa is not determined by the number of melanocytes in the epithelium but rather by their melanogenic activity. Pigmented biopolymers or melanins, are synthesiz...

Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies.

Abstract Hydrophobicity of PLA nanoparticles makes them a good substrate for macrophageal and reticulo-endothelial system uptake. Long-circulating properties can be imparted to these particles by coat...

beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration.

Abstract Context: Propranolol, atenolol, and ICI118,551 are non-selective β-adrenergic receptor (AR), β1-AR, and β2-AR antagonists, respectively. Objective: We investigated the efficacy of proprano...

Differences in Allosteric Communication Pipelines in the Inactive and Active States of a GPCR.

G-protein-coupled receptors (GPCRs) are membrane proteins that allosterically transduce the signal of ligand binding in the extracellular (EC) domain to couple to proteins in the intracellular (IC) do...

Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular α1-adrenergic receptor function.

Chemokine (C-X-C motif) receptor (CXCR) 4 and atypical chemokine receptor (ACKR) 3 ligands have been reported to modulate cardiovascular function in various disease models. The underlying mechanisms,...

Both JNK and P38 MAPK Pathways Participate in the Protection by Dexmedetomidine Against Isoflurane-Induced Neuroapoptosis in the Hippocampus of Neonatal Rats.

Dexmedetomidine, a highly selective α2-adrenergic agonist, has been reported to attenuate isoflurane-induced cognitive impairment and neuroapoptosis. However, the underlying molecular mechanisms rema...

EFFECTS OF MILD TO MODERATE SEDATION ON SACCADIC EYE MOVEMENTS.

Sedatives alter the metrics of saccadic eye movements. If these effects are nonspecific consequences of sedation, like drowsiness and loss of attention to the task, or differ between sedatives is stil...

Differential Regulation of Endosomal GPCR/Beta-arrestin Complexes and Trafficking by MAPK.

Beta-arrestins are signaling adaptors that bind to agonist-occupied G protein-coupled receptors (GPCRs) and target them for endocytosis; however, the mechanisms regulating receptor/β-arrestin complex...

News Articles [81 Associated News Articles listed on BioPortfolio]

Vasopressin more effective for cardiopulmonary resuscitation

Epinephrine has been shown to be a first-choice drug for cardiopulmonary resuscitation. Nevertheless, its β-adrenergic effect probably increases myocardial oxygen consumption and leads to severe card...

Alpha-adrenergic treatment improves QoL in obese LUTS men

Alpha-adrenergic medication can significantly improve the quality of life of obese men with lower urinary tract symptoms, show study findings.

Top stories in health and medicine, August 26, 2014

From MedPage Today: Adrenaline: The Best and Worst of Drugs. Despite it being the first-line adrenergic drug for patients with cardiac arrest, few studies in humans have assessed epinephrine’s...

Modifier Misuse Drives Increase in Practice Audits

Modifier misuse is costing your practice thousands in reimbursement, and RAC, OIG, & Medicare are targeting practices for audits based on modifier misuse. "Thi...

Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD

RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the f...

Stanford University partners small-molecule B1-ADR agonists with Cortice

Stanford University licensed Cortice Biosciences Inc. (cancer and CNS diseases) exclusive rights to a group of small-molecule beta-1 adrenergic receptor (B1-ADR) partial agonists, led by the preclinic...

Up-regulation of neuronal alpha-1 adrenoceptors after peripheral nerve injury

(Neural Regeneration Research) After nerve and tissue injury, inflammatory mediators could either directly, or through the induction of neurotrophic factors, trigger increased alpha-1-adrenoceptor exp...

Splicing Modifiers May Correct Spinal Muscular Atrophy Deficit

The journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficit...

Orally Delivered Compounds, Which Selectively Modify RNA Splicing Prevent Deficits In Mouse Models Of Spinal Muscular Atrophy

SOUTH PLAINFIELD, N.J., Aug. 7, 2014 /PRNewswire/ -- Today the journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers o...

Orally delivered compounds selectively modify RNA splicing, prevent deficits in SMA models

Today the journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing d...

Events [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...

Innate Therapeutics Limited

Innate Therapeutics Limited is a public unlisted biopharmaceutical company based in Auckland. The company is focused on the development of a new generation of immune response modi...

Clinical Trials [79 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage

The purpose of this study is to evaluate the clinical effect of esmolol treatment on cardiac function and electrophysiology; to assess the effects of esmolol treatment on serum adrenergic...

Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM)

To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.

Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy

OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic recept...

Occluded Artery Trial (OAT)

The purpose of this study is to determine whether opening an occluded infarcted artery 3-28 days after an acute myocardial infarction in high-risk asymptomatic patients reduces the composi...

Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA

The feasibility and dose-limiting toxicity of administering escalating doses of dendritic cells transfected with autologous renal cell carcinoma RNA DC(DCRCC-RNA) will be defined. As a sec...

Brain Receptors in Sympathetic Nervous System Regulation

The purpose of this study is to investigate the role of brain receptors called alpha2-adrenoreceptors in regulating the sympathetic nervous system, which maintains the supply of blood and...

Gene Modifiers of Cystic Fibrosis Lung Disease

Ths purpose of this study is to examine genetic modifiers of the severity of cystic fibrosis lung disease.

Genetics and Cardiovascular Reactivity in Young Twins

To evaluate the effects of genetic variants in all of the nine adrenergic receptor subtype genes, alone or in combination, on cardiovascular reactivity and other quantitative cardiovascula...

Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome

The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic prost...

The Role of Norepinephrine in Emotional Processing

This study will examine the role of a brain chemical called norepinephrine in thinking, decision-making, and emotional processing. After norepinephrine is released from a brain cell, it bi...

Medical and Biotech [MESH] Definitions

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE.

A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). beta-3 Adrenergic receptors are the predominant beta-adrenergic receptor type expressed in white and brown ADIPOCYTES and are involved in modulating ENERGY METABOLISM and THERMOGENESIS.

Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Search BioPortfolio:
Advertisement
Advertisement
review and buy Adrenergic modifiers market research data and corporate reports here

Channels Quicklinks